Targeted radioactive therapy for prostate cancer – Authors' reply
Targeted radioactive therapy for prostate cancer – Authors' reply
About this item
Full title
Author / Creator
Publisher
London: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Elif Hindié and colleagues ask about optimal radionuclides for use with prostate-specific membrane antigen (PSMA)-targeted approaches in the treatment of prostate cancer, and whether radionuclides other than lutetium-177 (177Lu) might deepen and extend the duration of responses. An advantage and disadvantage of 177Lu is its relatively long path len...
Alternative Titles
Full title
Targeted radioactive therapy for prostate cancer – Authors' reply
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2559671501
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2559671501
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(21)01060-6
